Form 4: Recursion Pharmaceuticals CEO Exercises Stock Options, Acquires Shares
SEC Form 4
Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 30, 2024.
Summary
- On August 30, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at a price of $2.48 per share.
- Following this transaction, Gibson directly owns 762,656 shares of Class A Common Stock.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
- He holds options to purchase additional shares at various exercise prices and vesting schedules.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The CEO exercising options could be seen as a slightly positive signal, but it's a routine filing.
Positives
- The CEO's decision to exercise stock options and increase his stake in the company could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The CEO's increased stake could boost investor confidence.
Key Dates
| Date | Description |
|---|---|
| 02/04/2022 | Date related to stock option (Right to Buy) with an exercise price of $11.4 and an expiration date of 02/04/2032. |
| 03/01/2022 | Initial vesting date for stock options originally for 416,350 shares, vesting monthly thereafter. |
| 03/01/2023 | Initial vesting date for stock options, vesting monthly thereafter. |
| 03/01/2024 | Initial vesting date for stock options originally for 666,898 shares, vesting monthly thereafter. |
| 08/30/2024 | Date of transaction: CEO exercised stock options to acquire shares. |
| 12/30/2030 | Expiration date for stock option (Right to Buy) with an exercise price of $2.48. |
| 02/04/2032 | Expiration date for stock option (Right to Buy) with an exercise price of $11.4. |
| 02/01/2033 | Expiration date for stock option (Right to Buy) with an exercise price of $8.55. |
| 02/09/2034 | Expiration date for stock option (Right to Buy) with an exercise price of $10.09. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.